A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Summary
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China and Southeast Asia. The NPC cells are poorly differentiated or undifferentiated with a high incidence of lymphatic and hematological dissemination. Because of the inherent anatomic constraints and a high degree of radiosensitivity, radiotherapy (RT) has been the primary treatment for NPC patients. NPC is also a chemosensitive tumor. Various modes of combined chemoradiotherapy have been used to treat NPC patients with advanced-stage diseases during recent 20 years. However, treatment outcome for locoregionally advanced NPC is still unsatisfactory.
Timeline
- Start
- 2014-12-14
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “Recruiting progress behind expectation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Epirubicin | Small molecule | — | — |
| Subject | Mitomycin C | Other / unclassified | — | — |
| Subject | tegafur-uracil | Small molecule | — | — |